Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model

Critical Care Medicine

Volumn 38, Issue 4, 2010, Pages 1162-1167

  Niemann, James T ^a,c   Youngquist, Scott ^d   Rosborough, John P ^a   Shah, Atman P ^a,c   Phan, Quynh T ^b   Filler, Scott G ^b,c  

^a Division of Cardiology   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiopulmonary resuscitation; Heart arrest; Hemodynamics; Interleukin; Tumor necrosis factor; Ventricular fibrillation

Indexed keywords

CYTOKINE; INFLIXIMAB; INTERLEUKIN 1BETA; PLACEBO; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEART ARREST; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESUSCITATION; STROKE; SWINE;

EID: 77950274228     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181d44324     Document Type: Article

References (35)

1. Nichol G, Steen P, Herlitz J, et al: International resuscitation network registry: Design, rationale and preliminary results. Resuscitation 2005; 65:265-277
2. Nichol G, Thomas E, Callaway CW, et al: Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA 2008; 300:1423-1431
3. Neumar RW, Nolan JP, Adrie C, et al: Post-cardiac arrest syndrome. Epidemiology, pathophysiology, treatment, and prognostication. Circulation 2008; 118:2452-2483
4. Gazmuri RJ, Weil MH, Kern KB, et al: Prevention and therapy of postresuscitation myocardial dysfunction. In: Cardiac Arrest. The Science and Practice of Resuscitation Medicine. Second Edition. Paradis NA, Halp-erin HR, Kern KB, et al (Eds). New York, NY, Cambridge University Press, 2007, pp 829-847
5. Gazmuri RJ, Ayoub IM, Kolarova J: Myocardial protection during resuscitation from cardiac arrest. Curr Opin Crit Care 2003; 9:199-204
6. Kern KB, Hilwig RW, Berg RA, et al: Pos-tresuscitation left ventricular systolic and diastolic dysfunction. Treatment with dobut-amine. Circulation 1997; 95:2610-2613
7. Niemann JT, Garner D, Khaleeli E, et al: Milrinone facilitates resuscitation from cardiac arrest and attenuates postresuscitation myocardial dysfunction. Circulation 2003; 108:1032-1036
8. Vasquez A, Kern KB, Hilwig RW, et al: Optimal dosing of dobutamine for treating post-resuscitation left ventricular dysfunction. Resuscitation 2004; 61:199-207
9. Boros P, Bromber JS: New cellular and molecular immune pathways in ischemia/ reperfusion injury. Am J Tranplant 2006; 6:652-658
10. Stangl V, Baumann G, Stangl K, et al: Negative inotropic mediators from heart after myocardial ischaemia-reperfusion. Cardio-vasc Res 2002; 53:12-30
11. Kan H, Finkel MS: Inflammatory mediators and reversible myocardial dysfunction. J Cell Physiol 2003; 195:1-11
12. Ito T, Saitoh D, Fukuzuka K, et al: Significance of elevated serum interleukin-8 in patients resuscitated after cardiac arrest. Resuscitation 2001; 51:47-53
13. Adrie C, Adib-Conquy M, Laurent I, et al: Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation 2002; 106:562-568
14. Niemann JT, Garner D, Lewis RJ: Tumor necrosis factor-a is associated with early postresuscitation myocardial dysfunction. Crit Care Med 2004; 32:1753-1758
15. Dunnett CW: A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc 1955; 50: 1096-1121
16. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 1998; 174:R577-R595
17. Yokoyama T, Vaca L, Rossen RD, et al: Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312
18. Gulick T, Chung M, Pieper SJ, et al: Inter-leukin 1 and tumor necrosis factor inhibit cardiac myocytes beta-adrenergic responsiveness. Proc Natl Acad Sci 1989; 86: 6753-6757
19. Kumar A, Kosuri R, Kandula P, et al: Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes. Crit Care Med 1999; 27: 286-292
20. Bucher M, Kees F, Taeger K, et al: Cytokines down-regulate a-1 adrenergic receptor expression during endotoxemia. Crit Care Med 2003; 31:566-571
21. Li D, Zhao L, Liu M, et al: Kinetics of tumor necrosis factor a and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor a in acute myocardial infarction. Am Heart J 1999; 137:2245-2252
22. Pauli U: Porcine TNF: A review. Vet Immunol Immunopathol 1995; 47:187-201
23. Pauli U, Beutler B, Peterhans E: Porcine tumor necrosis factor alpha: cloning with the polymerase chain reaction and determination of the nucleotide sequence. Gene 1989; 81:185-191
24. Pauli U, Bertoni G, Duerr M, et al: A bioassay for the detection of tumor necrosis factor from eight different species: Evaluation of neutralization rates of monoclonal antibody against human TNF-a. J Immunol Meth 1994; 171:263-265
25. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci 1997; 94:3195-3199
26. Holmes CL, Russell JA, Walley KR: Genetic polymorphisms in sepsis and septic shock. Role in prognosis and potential for therapy. Chest 2003; 124:1103-1115
27. Imahara SD, O'Keefe GE: Genetic determinants of the inflammatory response. Curr Opin Crit Care 2004; 10:318-324
28. Niemann JT, Rosborough JP, Youngquist S: Is the tumor necrosis factor-alpha response following resuscitation gender dependent in the swine model? Resuscitation 2008; 77: 258-263
29. Chung ES, Packer M, Lo KH, et al: Randomized double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure. Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) Trial. Circulation 2003; 107:3133-3140
30. Abraham E, Anzueto A, Guitierrez G, et al: Double-blind randomised controlled trial of monclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-933
31. Wu X, Stezoski J, Safar P, et al: Mild hypothermia during hemorrhagic shock in rats improves survival without significant effects on inflammatory responses. Crit Care Med 2003; 31:195-202
32. Callaway CW, Rittenberger JC, Logue ES, et al: Hypothermia after cardiac arrest does not alter serum inflammatory markers. Crit Care Med 2008; 36:2607-2612
33. Anker SD, Coates AJS: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL, and ATTACH. Int J Cardiol 2002; 86:123-130
34. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intens Care Med 1999; 25:556-566
35. Kellum JA, Kong L, Fink MP, et al: Understanding the inflammatory cytokine response in pneumonia and sepsis. Results of the genetic and inflammatory markers of sepsis (GemIMS) study. Arch Intern Med 2007; 167: 1655-1663